Outset is a pioneering medical technology company reimagining dialysis for patients and health care providers.
Advisors
Dr. Alvarez serves as Outset’s Chief Technology and Innovation Advisor, and is currently the Chair of Nephrology at the Palo Alto Medical Foundation, Sutter Health. Following his doctoral work in biophysics, he worked in the pharmaceutical and device industries. A former advisor to the Stanford Biodesign Department, Dr. Alvarez remains committed to the application of industrial continuous quality improvement concepts to the field of nephrology, including transformation of the acute renal failure care model both in the intensive unit and sub-acute hospital settings. In this capacity he also serves as a consultant to Satellite Dialysis acute care services. In addition, Dr. Alvarez works as a Medical Director for Satellite Dialysis and Wellbound Home Dialysis where he is active on the Medical Policy Committee. While maintaining a clinical practice, Dr. Alvarez devotes his time at the Palo Alto Medical Foundation working on integration of clinical services across divisions with the formation of medical service lines and development of shared risk models of payment reform.
Dr. Chertow is the Norman S. Coplon/Satellite Healthcare Professor of Medicine and Chief, Division of Nephrology at Stanford School of Medicine. His research interests are focused on epidemiology, health services research, and clinical trials in acute and chronic kidney disease. Dr. Chertow is involved in research sponsored by the National Institutes of Health and has written numerous papers on end-stage renal disease, acute renal failure, nutrition, mineral metabolism, and the costs and outcomes of dialysis therapy. He serves on the Board of Directors for Satellite Healthcare, Inc. and on the Scientific Advisory Board of DaVita Clinical Research. He is Co-Editor of Brenner and Rector’s The Kidney, a leading nephrology textbook. He also serves on the editorial boards of the Journal of the American Society of Nephrology (JASN) and Clinical Journal of the American Society of Nephrology (CJASN). He has served as an Advisor to MedPAC, for issues related to dialysis care. Dr. Chertow has designed and/or monitored several NIH- and industry-sponsored cohort studies and clinical trials in kidney disease, including CRIC, ATN, FHN, DAC, SPRINT, TREAT, ADVANCE and EVOLVE. In addition to his research and teaching activities, Dr. Chertow has an active clinical practice focused on inpatient and outpatient nephrology care.
Dr. Prichard has had an academic career at McGill University, Montreal Canada, followed by a career in industry at Baxter Healthcare. Currently, she serves on various corporate boards, on Scientific Advisory Boards and as a consultant. Dr. Prichard received her MD from Queens University at Kingston and then completed her training in Internal Medicine and Nephrology at McGill University. She joined the faculty of McGill University in 1979 and remained there until 2005. At McGill she was a Professor of Medicine, served as Associate Dean for the Faculty of Medicine and became President of the Canadian Society of Nephrology (1997-2000) and the International Society for Peritoneal Dialysis (2001-2004). She published and taught widely with a focus on peritoneal dialysis and cardiovascular disease. In 2005, Dr. Prichard was recruited to Baxter Healthcare as Global Vice President for Medical and Scientific Affairs in the Renal business. During a nine-year tenure at Baxter, she held a number of senior leadership roles within the Renal as well as the Specialty Pharma therapeutic areas. Responsibilities included global medical affairs, clinical development, health economics, and scientific and clinical input for new product development and product life cycle management.
Board of Directors
Leslie joined Outset from Warburg Pincus where she was an Executive in Residence. Previously, she was Executive Vice President at Lutonix, a cardiovascular medical device company acquired by CR Bard. Prior to Lutonix, Leslie served as Chief Business Officer of AccessClosure, a vascular closure company acquired by Cardinal Health. Before joining AccessClosure, she was the Vice President, Marketing for FoxHollow Technologies, helping to architect the strategy and commercial infrastructure that led to a successful IPO and subsequent acquisition by ev3/Covidien. Leslie’s management experience also includes senior leadership positions at Cytyc Corporation and breast cancer diagnostics company Pro-Duct Health, Inc., which was acquired by Cytyc. She began her medical device career at Guidant Corporation. Leslie received her undergraduate degree from Northwestern University and her MBA from the Haas School of Business, UC Berkeley.
Keith has been a leader in the medical technology industry for more than 30 years. He is currently the President and CEO of Nevro Corporation (NVRO). Prior to Nevro, he was named President and CEO of Thoratec Corp (THOR) for the second time in 2014. Keith led the company’s return to growth, a 2.5x increase in company value and its $3.4 billion acquisition by St. Jude Medical in 2015. He previously served as the CEO, President and Director of Conceptus, Inc. (CPTS) from 2011 to 2013, where he took the company from negative sales growth to over 20% growth, tripled EBIDTA, and led the company’s sale to Bayer Healthcare for over $1.1 billion, a 3x increase in the company’s value prior to his arrival. From 2007 to 2011, Keith served as Managing Director for TPG Biotech, the $1.1 billion venture capital arm of the private equity firm Texas Pacific Group (TPG). Prior to TPG, he served as CEO, President and Director of Thoratec Corporation from 1996 to 2006, increasing the company’s market value more than 12x, and leading the company from no revenue to more than $200 million in annual revenues. Prior to Thoratec, Keith held a number of commercial and general management roles with companies including SulzerMedica and American Hospital Supply Corp. Keith serves as a Director of ViewRay, Inc., Vyaire Medical and TherOx, Inc., and he is a former member of the Board of Directors of Intuitive Surgical, Inc. (ISRG), Kyphon, Inc. (KYPH), Zeltiq (which was acquired by Allergan in 2017), and a number of private medical technology companies.
Jim has 30 years of financial leadership experience in large and small organizations within the healthcare industry. He currently serves as a Director of Orthofix Inc. (OFIX), Integer Holdings (ITGR), Acutus Medical and Signifier Medical. Prior to these board roles, Jim served as Chief Financial Officer (CFO) of multiple companies: From 2018-2019, he was CFO of Cibus, a startup gene-editing company focused on the agriculture markets; From 2015 to 2017, he was Executive Vice President and Chief Financial Officer of Alere Inc, a publicly traded diagnostic company, until its sale to Abbott Labs for approximately $8 billion; From 2010 to 2015, he was CFO of CareFusion Corporation, a publicly traded medical technology company, until its sale to Becton Dickinson for approximately $12 billion. He previously served at Cardinal Health in various financial leadership positions including Executive Vice President and Corporate Controller of Cardinal Health and as Executive Vice President and Chief Financial Officer of its Healthcare Supply Chain Services segment. He joined Cardinal Health following more than a decade of finance and marketing roles at Merck & Co. He holds undergraduate and graduate degrees in business from Carnegie Mellon University and is an inactive Chartered Financial Analyst (CFA).
Ali Osman joined Mubadala Investment Company in 2010. Based in Abu Dhabi in the United Arab Emirates, he serves as a Senior Vice President in Mubadala’s Pharma & Medtech principal investments team. Ali served as a Board Director for several companies, and is currently a Director of Sterling Pharma Solutions, a private company in the CDMO space. Ali has worked across multiple industries within the principal investment field covering North America, Europe, Asia and the MENA region, with a focus on healthcare and technology. Ali obtained his Bachelor of Science in Mechanical Engineering from Tufts University and earned his M.B.A. from Harvard Business School.
Patrick T. Hackett is a Special Limited Partner of Warburg Pincus. He joined Warburg Pincus in 1990 and in his 29 years at Warburg Pincus, he has focused on investments in the technology and health care services fields. Prior to joining Warburg Pincus, he was the Vice President of Cove Capital Associates, a private merchant banking partnership, and prior to that a Partner with private equity firm, Acadia Partners. Mr. Hackett is a Director of Intelligent Medical Objects, a private healthcare software company. In addition, he serves on the Board of Directors at Stamford Health System, a nonprofit community hospital in Connecticut. Mr. Hackett graduated from the University of Pennsylvania with a B.A. in chemistry, and holds a B.S. in economics from the Wharton School at the University of Pennsylvania.
Thomas “TJ” Carella joined Warburg Pincus in 2016. Based in New York, he serves as a Managing Director with a focus on Healthcare investing. He is a Director of Alignment Healthcare, CityMD/ Summit Medical Group, Outset Medical, Specialist on Call and Vertice Pharma. Prior to joining Warburg Pincus, TJ was a Partner in the Merchant Banking Division of Goldman Sachs and Global Head of the division’s Private Equity activities in the Healthcare sector. While at Goldman Sachs, he led, or was actively involved in, the following investments: Advanced Recovery Systems, Assuramed, Drayer Physical Therapy, Globus Medical, Golden State Medical Supply, iHealth Technologies, Magnacare, Press Ganey, Privia Health, T2Biosystems, and Vitals Health. He earned his bachelor’s degree from Harvard College and then obtained his M.B.A. from Harvard Business School.